Cardiac Device Therapy for Heart Failure: An individualized approach









  • Views:

    Views Icon 2764
  • Likes:

    Heart Icon 11


In this webinar, international experts review the latest evidence in cardiac resynchronization therapy in light of contemporary heart failure medications and the latest analyses on their combination with implantable cardiac defibrillators.

Specifically, the panel discuss the recent HFA, EHRA and EACVI position paper on the optimized Implementation of CRT and its recommended actions:

  1. Overcoming the underutilization of CRT therapy
  2. Evaluating and understanding better the pre-implant characteristics
  3. Critically evaluating terms such as ‘non‐response’ together with the concept of disease modification
  4. Implementation of a dedicated care pathway for CRT patients post-implant

Performed By:

Cecilia Linde

Cecilia Linde

Wilfried Mullens

Wilfried Mullens

Michael R Gold

Michael R Gold

This webinar is supported by:



Prof Cecilia Linde

Key learnings of the HFA/EHRA consensus paper on CRT Optimization

Prof Wilfried Mullens

Q&A Session

All Faculty

Drugs and devices for heart failure: What did we learn from the ICD/CRT-D analysis of PARADIGM-HF?

Dr Michael Gold

Q&A Session

All Faculty

Final discussion and closing remarks

Prof Cecilia Linde

Learning Objectives

This webinar is to inform cardiologists how to optimize the individual drug and cardiac device therapy to obtain the best patient’s outcome. Specifically, in each examined area, the viewers will gain a unique contemporary perspective on the:

  • Underlying behaviors leading to substantial underutilization of CRT therapy (with and without a combined implantable cardioverter defibrillator), how these can be addressed/overcome.
  • How contemporary pharmaceutical regimens may be impacting timely CRT referral to the detriment of therapeutic synergies and optimal patient outcomes.
  • Analyses and research on the various pre-implant characteristics that can impact the decision to implant CRT therapy and the exact device selection (CRT-D vs CRT-P).
  • Historical background and evolution of the term “response” and “non-response” to CRT therapy and why these terms may have been used outside of their appropriate context in a therapy area that is by its nature progressive.
  • Level of care that needs to be provided after a CRT device is implanted and practical ways of implementing such pathways across international care settings.


  • Cardiologists and electrophysiologists involved in the implantation and follow-up of cardiac implantable devices for heart failure, such as implantable cardioverter defibrillators (ICDs) and Cardiac Resynchronization Therapy device (CRT)

Faculty Biographies

Cecilia Linde

Cecilia Linde

Cecilia Linde is professor and consultant in cardiology at the Karolinska University Hospital in Stockholm, Sweden. Her research focuses on epidemiology and devices for use in heart failure.

Dr Linde is the author of more than 250 papers, reviews and editorials in a wide variety of fields including CRT, haemodynamic monitoring and HFpEF and she serves on the editorial board of several journals. She has been a board member of the European Heart Rhythm Association (EHRA) for which she was scientific programme Chair 2013–2015 and has served on many guidelines writing committees of EHRA and Heart Failure Association. Currently Dr Linde is co-PI of the European CRT survey II covering 11,088 CRT implantations across 42 European countries.

View full profile
Wilfried Mullens

Wilfried Mullens

Prof Wilfried Mullens is a heart failure clinician with a strong commitment to translational research translating new mechanistic insights into answering questions of clinical interest. He has been president of the Belgian Working Group on Heart Failure and serving as board member of European Heart Failure Association (HFA) leading the committee on cardiac devices.

View full profile
Michael R Gold

Michael R Gold

Dr Gold received a PhD in Physiology from the University of Virginia and an MD degree from the University of Colorado.  His postgraduate medical training and fellowships in Internal Medicine, Cardiology and Electrophysiology were at Massachusetts General Hospital and Harvard Medical School.  Immediately following, he joined the faculty of University of Maryland where he was the director of the cardiac EP service and Professor of medicine in the Department of Medicine.  In 2002, Dr. Gold moved to Charleston, SC where he assumed the role of Chief of Cardiology and Medical Director of the Heart & Vascular Center at the Medical University of South Carolina. He subsequently was appointed as an Associate Dean of Interdisciplinary Clinical programs.  Presently, he is the Michael E. Assey Professor of Medicine.

Dr. Gold is a past President of Heart Rhythm Society and the Association of Professors of Cardiology. He has authored more than 270 publications and more than 30 book chapters and reviews.  He has been on the steering committee and/or the study PI of more than 15 multicenter trials. He is a pioneer in the development of new defibrillation and pacing techniques.

Dr. Gold is the Editor-in- Chief of Current Cardiology Risk Reports, an associate Editor-in-Chief of International Journal of Heart Rhythm, an Associate Editor for Heart Rhythm and a senior editor for the Journal of the American College of Cardiology.  He also serves on the Editorial Board of The American Journal of Cardiology, PACE, JACC EP, Circulation AE, Journal of Cardiovascular Electrophysiology, US Cardiology Review and Current Cardiology Reports.     

Dr Michael R Gold is an Editorial Board member of US Cardiology Review.

View full profile

Key References

1. Mullens W et al. Optimized Implementation of cardiac resynchronization therapy – a call for action for referral and optimization of care A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail 2020, advance access published November 2, 2020

2. Rohde LE et al. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. A PARADIGM-HF Analysis. JACC Heart Fail. 2020 Oct;8(10):844-855